Detalhe da pesquisa
1.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Lancet Oncol
; 16(13): 1306-15, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26338525
2.
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Int J Cancer
; 136(1): 83-90, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24806288
3.
Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.
Mod Pathol
; 28(4): 487-97, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341653
4.
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
BMC Cancer
; 15: 874, 2015 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553291
5.
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.
Mod Pathol
; 25(1): 46-55, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21909080
6.
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Lancet Oncol
; 11(9): 845-52, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20702138
7.
Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series.
Diagnostics (Basel)
; 11(6)2021 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34200245
8.
Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation.
J Mol Diagn
; 22(5): 685-698, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32173570
9.
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy.
Front Oncol
; 9: 1390, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31921647
10.
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Eur J Cancer
; 110: 32-41, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739838
11.
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
Eur J Cancer
; 109: 175-182, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30735919
12.
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.
Exp Hematol Oncol
; 6: 6, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28344857
13.
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.
Genes Cancer
; 8(1-2): 438-452, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28435517
14.
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Eur J Cancer
; 73: 74-84, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27986363
15.
RNA-based analysis of BRCA1 and BRCA2 gene alterations.
Cancer Genet Cytogenet
; 170(2): 93-101, 2006 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17011978
16.
Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Cancer Cytopathol
; 124(5): 340-9, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26749005
17.
Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience.
J Clin Endocrinol Metab
; 101(11): 4413-4420, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27571181
18.
EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.
Oncol Rep
; 36(2): 1166-72, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27373829
19.
Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion.
Eur J Hum Genet
; 12(9): 775-7, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15162129
20.
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Cancer Cytopathol
; 122(6): 445-53, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24648382